Novakand Pharma AB (publ) (ST:LARK) — Market Cap & Net Worth
Market Cap & Net Worth: Novakand Pharma AB (publ) (LARK)
Novakand Pharma AB (publ) (ST:LARK) has a market capitalization of $4.90 Million (Skr45.54 Million) as of July 13, 2026. Listed on the ST stock exchange, this USA-based company holds position #28666 globally and #5815 in its home market, demonstrating a -0.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novakand Pharma AB (publ)'s stock price Skr2.30 by its total outstanding shares 19801197 (19.80 Million). See LARK capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Novakand Pharma AB (publ) Market Cap History: 2025 to 2026
Novakand Pharma AB (publ)'s market capitalization history from 2025 to 2026. Data shows growth from $4.82 Million to $4.90 Million (0.00% CAGR).
Novakand Pharma AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novakand Pharma AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of LARK by Market Capitalization
Companies near Novakand Pharma AB (publ) in the global market cap rankings as of July 13, 2026.
Key companies related to Novakand Pharma AB (publ) by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #148 globally with a market cap of $160.84 Billion USD.
- Brookfield Corporation (TO:BN): Ranked #252 globally with a market cap of $100.63 Billion USD ( CA$139.11 Billion CAD).
- Blackstone Group Inc (NYSE:BX): Ranked #278 globally with a market cap of $91.44 Billion USD.
- KKR & Co. Inc. (NYSE:KKR): Ranked #298 globally with a market cap of $87.04 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #148 | BlackRock Inc | NYSE:BLK | $160.84 Billion | $1036.11 |
| #252 | Brookfield Corporation | TO:BN | $100.63 Billion | CA$61.98 |
| #278 | Blackstone Group Inc | NYSE:BX | $91.44 Billion | $123.09 |
| #298 | KKR & Co. Inc. | NYSE:KKR | $87.04 Billion | $96.94 |
Novakand Pharma AB (publ) Historical Marketcap From 2025 to 2026
Between 2025 and today, Novakand Pharma AB (publ)'s market cap moved from $4.82 Million to $ 4.90 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr4.90 Million | +1.77% |
| 2025 | Skr4.82 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 12th, 2026 the market cap of Novakand Pharma AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.90 Million USD |
| MoneyControl | $4.90 Million USD |
| MarketWatch | $4.90 Million USD |
| marketcap.company | $4.90 Million USD |
| Reuters | $4.90 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novakand Pharma AB (publ)
Lärkberget AB (publ) operates as an investment company. The company is involved in direct investments in low-risk instruments, and unlisted profitable companies; financial investments; and reverse acquisition business. It also invests in listed shares, funds and other liquid asset classes, as well as participates in bridge loans and guarantee commitments. The company was formerly known as CombiGe… Read more